Tech Times on MSN
Korean biotech files US IND for RNAi drug targeting MyD88 amplifier in geographic atrophy
Geographic atrophy treatment has a new entrant: OliX Pharmaceuticals filed a US IND for OLX301A, a siRNA drug targeting MyD88, the retinal inflammation amplifier Syfovre and Izervay cannot silence.
Teva ends its Phase II TOPAS-MSA emrusolmin trial in multiple system atrophy after a futility analysis. Read now to see what it means for MSA patients.
Patients with geographic atrophy prefer treatments that preserve reading ability and distance vision despite potential risks of inflammation.
Israeli drugmaker Teva Industries said it will discontinue its Phase II TOPAS-MSA study of emrusolmin (TEV-‘286) in adults with multiple system atrophy (MSA), after an interim analysis indicated a ...
Emrusolmin is being developed in partnership with MODAG GmbH. Teva said the decision concerns TOPAS-MSA and does not represent a final decision on the broader emrusolmin program. In pre-market trading ...
Teva Pharmaceutical Industries is discontinuing a Phase 2 study for a multiple system atrophy treatment. The company said Monday the move follows a recommendation from an independent data monitoring ...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries ( TEVA ), said it will discontinue its Phase 2 TOPAS-MSA study evaluating emrusolmin (TEV-‘286) in adults with multiple system ...
Dan4Neo Both the story and gameplay of spec ops the line is really bad. Why do people still talk about this game?
KOZHIKODE: In an unprecedented display of grassroots solidarity, mountainous Mukkam, in Kozhikode, has transformed into a ...
Patient-specific CFD models show that lower false-lumen flow near the renal arteries emerges early after aortic dissection ...
South Africa: 'I Need More Support' - KZN Mother Raising Three Children With Spinal Muscular Atrophy
Mother has no transport for three disabled children to access medical care. Special needs schooling is put on hold. Councillor says they plan to construct an accessible toilet.
(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results